Bayer said the patent panel's order weakens the international patent system and endangers pharmaceutical research.

NPR: India Rejects Bayer Plea Against Cheap Cancer Drug

The order "weakens the international patent system and endangers pharmaceutical research, " the company said in a statement.

WSJ: India Rejects Bayer's Nexavar Plea